Brokers Issue Forecasts for Humana Inc.’s Q3 2024 Earnings (NYSE:HUM)

Humana Inc. (NYSE:HUM) – Stock analysts at Leerink Partnrs dropped their Q3 2024 earnings estimates for shares of Humana in a note issued to investors on Wednesday, April 24th. Leerink Partnrs analyst W. Mayo now anticipates that the insurance provider will post earnings of $4.08 per share for the quarter, down from their prior forecast of $4.38. The consensus estimate for Humana’s current full-year earnings is $16.08 per share. Leerink Partnrs also issued estimates for Humana’s Q4 2024 earnings at ($1.86) EPS, Q1 2025 earnings at $8.76 EPS, Q3 2025 earnings at $5.75 EPS, Q4 2025 earnings at ($0.56) EPS and FY2025 earnings at $22.16 EPS.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. Humana’s revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $9.38 earnings per share.

Several other equities analysts have also recently weighed in on the company. The Goldman Sachs Group cut their price objective on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, April 3rd. Raymond James assumed coverage on shares of Humana in a report on Friday, March 22nd. They issued a “market perform” rating on the stock. Wells Fargo & Company decreased their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Deutsche Bank Aktiengesellschaft cut Humana from a “buy” rating to a “hold” rating and decreased their target price for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. Finally, Oppenheimer lowered their price objective on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Humana currently has a consensus rating of “Hold” and an average price target of $424.50.

Humana Stock Down 0.3 %

HUM stock opened at $302.09 on Monday. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. Humana has a 12-month low of $299.23 and a 12-month high of $541.21. The company has a 50 day moving average of $325.94 and a two-hundred day moving average of $392.00. The company has a market cap of $36.40 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 1.79 and a beta of 0.45.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.17%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Insider Activity at Humana

In other Humana news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the acquisition, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.29% of the stock is owned by insiders.

Hedge Funds Weigh In On Humana

A number of institutional investors have recently added to or reduced their stakes in the stock. Auxano Advisors LLC bought a new stake in Humana during the 4th quarter worth approximately $540,000. Mariner LLC increased its holdings in Humana by 2.3% during the 3rd quarter. Mariner LLC now owns 14,119 shares of the insurance provider’s stock worth $6,869,000 after purchasing an additional 312 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Humana by 27.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider’s stock valued at $13,595,000 after buying an additional 6,034 shares during the last quarter. Silverarc Capital Management LLC purchased a new stake in shares of Humana in the third quarter valued at about $4,865,000. Finally, Vest Financial LLC increased its stake in Humana by 43.3% in the 4th quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock valued at $12,815,000 after buying an additional 8,455 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.